We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Patients are the centre and the core of our system. We are professionals committed to quality care and our organizational structure breaks down the traditional boundaries between departments and professional groups, with an exclusive model of knowledge areas.
Would you like to know what your stay at Vall d'Hebron will be like? Here you will find all the information.
The commitment of Vall d'Hebron University Hospital to innovation allows us to be at the forefront of medicine, providing first class care adapted to the changing needs of each patient.
Prostate cancer is the tumor most frequently diagnosed in adult men in developed countries with a long life expectancy. It is an atypical and uncontrolled growth of the cells that make up the prostate gland.
If there is suspicion due to symptoms or an elevated PSA, a digital rectal exam and a new blood PSA test will be performed. If the rectal exam is positive (a nodule or hardening of the prostate is detected), a biopsy will be carried out. If the rectal exam is negative, PSA levels will be evaluated to decide whether a biopsy is necessary. PSA is used as a screening tool in the general population to enable early diagnosis of prostate cancer.
It is a good tumor marker because it increases when the prostate glands are disrupted due to tumor growth. Since it is also present in the normal prostate and increases in benign prostate growth, it must always be interpreted in the individual context of each patient. An elevated PSA is not synonymous with prostate cancer, and a rectal exam and ultrasound should always be performed. The final diagnosis is made only by biopsy.
Risk factors for developing the disease include:
The typical profile is a man aged 50–70 years, in whom benign prostate growth may coexist.
Many men with prostate cancer are asymptomatic.
Often, the first sign of the disease is a casual finding of an elevated prostate-specific antigen (PSA) in a routine blood test. Sometimes the disease can produce local symptoms related to the growth of the prostate gland, which may mimic those caused by benign prostatic hyperplasia. In these patients, bone pain is usually associated with more advanced stages of the disease.
Experiencing urinary discomfort does not necessarily mean you have prostate cancer. Consult your doctor if you have any of these symptoms to ensure you receive an accurate diagnosis and appropriate treatment.
Prostate cancer is diagnosed through serum PSA levels, digital rectal exam, and ultrasound-guided prostate biopsy.
Prostate biopsies can cause some complications, which in most cases resolve without lasting effects. The most common are:
When prostate cancer is localized and low-risk, it can be treated with surgical removal and radiotherapy. In cases of spread, treatment with radiotherapy and hormones is considered to slow tumor growth. Sometimes, if the patient is elderly, the progression of the cancer is closely monitored before surgery, as in some cases it does not pose a short-term threat to survival.
Prostate cancer survival depends on the stage at the time of diagnosis: it is quite favorable in localized cases, less favorable in advanced cases, and worst in disseminated cases. For this reason, periodic evaluation of the prostate by a primary care physician is recommended.
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.